Citigroup’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Citigroup’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13	Closed	-$137	–	5835
2026 Q1	$137	Sell	13 -1,159	-99%	-$1.65K	﹤0.01%	5596
2025 Q4	$10.4K	Buy	+1,172	New	+$2.09K	﹤0.01%	5041
2021 Q2	–	Sell	-10	Closed	-$4K	–	6168
2021 Q1	$4K	Sell	10 -21	-68%	-$1.58K	﹤0.01%	5934
2020 Q4	$13K	Buy	31 +23	+288%	+$1.57K	﹤0.01%	6856
2020 Q3	$6K	Sell	8 -15	-65%	-$1.72K	﹤0.01%	6890
2020 Q2	$19K	Sell	23 -25	-52%	-$2.09K	﹤0.01%	6646
2020 Q1	$18K	Sell	48 -13	-21%	-$927	﹤0.01%	6749
2019 Q4	$23K	Buy	61 +20	+49%	+$1.87K	﹤0.01%	6865
2019 Q3	$69K	Sell	41 -4	-9%	-$864	﹤0.01%	5919
2019 Q2	$71K	Buy	+45	New	+$12.7K	﹤0.01%	6162

Other funds holding KRSA

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Citigroup's KRSA Position: Q2 2026 in Review

Citigroup sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q2 2026, closing a stake of 13 shares — an estimated $137 sold.

Citigroup first reported a position in KRSA in Q2 2019 and held it in 10 quarters. The position peaked at $71K in Q2 2019. 21 funds tracked by Wall St. Rank hold KRSA as of Q2 2026.

Citigroup reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
Citigroup sold 13 Korsana Biosciences, Inc. Common Stock shares in Q2 2026, an estimated $137.
Citigroup first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 10 quarters.
Citigroup's Korsana Biosciences, Inc. Common Stock position peaked at $71K in Q2 2019.
21 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.